German biotech firm Evotec (EVT: Xetra) has signed a deal to in-license more than 10 infectious disease (ID) assets from French drug major Sanofi (Euronext: SAN).
Evotec will also licence-in the majority of Sanofi's ID research portfolio and initiatives and will receive 60 million euros ($70 million) upfront from the Paris-based company along with additional, significant long-term funding to ensure the progression of the anti-infectives portfolio.
"Evotec will have created the highest qualified translational footprint in infectious disease research globally"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze